About this trial
Patients with stroke frequently suffer from aphasia, a disorder of expressive and/or receptive language, that can lead to serious health consequences, including social isolation, depression, reduced quality of life, and increased caregiver burden. Aphasia recovery varies greatly between individuals, and likely relies upon the capacity for neuroplasticity, both at a systems level of reorganized brain networks and a molecular level of neuronal repair and plasticity. The proposed work will evaluate genetic and neural network biological markers of neuroplasticity associated with variability in aphasia, with a future goal to improve prognostics and identify therapeutic targets to reduce the long-term burdens of aphasia.
Eligibility criteria
Qualifiers
Ages 40-90
Right-handed (prior to stroke)
Proficient English speakers
History of a single ischemic stroke in the middle cerebral artery territory that is lateralized to the left or right (Aim 1) cerebral hemisphere.
Disqualifiers
History of significant medical or neurological disorder (other than stroke)
History of significant or poorly controlled psychiatric disorders
Current abuse of alcohol or drugs, prescription or otherwise
Clinically significant and uncorrected vision or hearing loss
Trial design
Treatments tested in this trial
- Pseudoword learning paradigm task
Treatment groups
Sponsors and collaborators
University of Wisconsin, Madison
Lead sponsor
National Institutes of Health (NIH)
Collaborator
National Institute on Deafness and Other Communication Disorders (NIDCD)
Collaborator